Calaspargase pegol - Servier
Alternative Names: ASPARLAS; Cal-PEG; EZN-2285; Oncaspar-IV; S9-5015; SC-PEG E. coli L-asparaginase; Scalasparagase pegol; SHP-663Latest Information Update: 07 Jun 2022
At a glance
- Originator Enzon Pharmaceuticals
- Developer Children's Oncology Group; Dana-Farber Cancer Institute; Leadiant Biosciences; National Cancer Institute (USA); Servier
- Class Amidohydrolases; Antineoplastics; Polyethylene glycols
- Mechanism of Action Aspartate-ammonia ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Precursor cell lymphoblastic leukaemia-lymphoma
- Phase II Haematological malignancies
- No development reported Acute myeloid leukaemia
Most Recent Events
- 30 Apr 2022 Phase-II clinical trials in Haematological malignancies (IV) before April 2022 (Servier pipeline, June 2022)
- 28 May 2019 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in Unknown (IV)
- 08 Jan 2019 Shire has been acquired and merged into Servier